Thyroid Eye Disease: Unmasking and Taming What’s in Disguise

Thyroid eye disease (TED) is a complex autoimmune-mediated inflammatory disorder of the orbit that is associated with a spectrum of signs and symptoms and varying levels of severity. Early diagnosis and initiation of appropriate treatment are imperative for preventing progression to severe disease and potential vision loss. However, diagnosis can be challenging. Traditional treatments for TED, such as steroids, radiotherapy, and surgery, all relieve symptoms but do not alter the course of disease. Newly approved and emerging monoclonal antibodies targeting the insulin-like growth factor 1 receptor have demonstrated efficacy in the management of TED, including patients with low clinical activity scores, resulting in a paradigm shift in disease management. In this CE monograph, experts in the field review risk factors and classification criteria that aid in the timely differential diagnosis of TED and evaluate treatment strategies that exhibit a favorable benefit-risk profile to improve outcomes and patient satisfaction. Challenging real-world cases will also be presented, allowing for application of the content into clinical practice.